Form 4: Disc Medicine Director Sells Shares

A director at Disc Medicine, Kevin Bitterman, reported multiple indirect sales of common stock totaling 93,535 shares across several investment funds.

Summary

• Kevin Bitterman, a Director of Disc Medicine, Inc. (IRON), reported multiple transactions involving the sale of common stock.
• These transactions occurred on October 15, 16, and 17, 2025.
• A total of 93,535 shares were sold indirectly through Atlas Venture Opportunity Fund I, LP, Atlas Venture Opportunity Fund II, LP, and Atlas Venture Fund XII, L.P.
• The sales were executed at weighted average prices ranging from $76.52 to $92.15 per share.
• The transactions were made pursuant to a Rule 10b5-1(c) pre-arranged trading plan.
• Following these transactions, the indirect beneficial ownership of shares by the funds associated with Mr. Bitterman decreased.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to significant insider selling, even though it was pre-planned under a 10b5-1 program. While 10b5-1 plans mitigate the immediate negative signal, large sales by a director can still raise questions about long-term conviction or personal liquidity needs.

Positives

• The transactions were conducted under a Rule 10b5-1(c) plan, indicating pre-scheduled sales rather than immediate market reaction based on new, non-public information.

Negatives

• A director, albeit indirectly through associated funds, sold a significant number of shares (93,535 shares), which can sometimes be perceived negatively by the market.

Risks

• Potential negative market perception due to insider selling, which could put downward pressure on the stock price.
• The disclaimer of beneficial ownership by the reporting person, except for pecuniary interest, highlights the complex ownership structure through investment funds, which may require further scrutiny by investors.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The reporting person disclaims beneficial ownership of such securities held by the investment funds, except to the extent of his pecuniary interest therein, if any.

Industry Context

Insider transactions, particularly sales, are closely watched in the biotechnology and pharmaceutical sectors as they can sometimes signal management's confidence (or lack thereof) in the company's near-term prospects. However, sales under a 10b5-1 plan are generally viewed as less indicative of a change in sentiment compared to open market sales without such a plan.

Comparison to Industry Standards

• NA

Related Party Transactions

• The transactions involve sales of common stock by investment funds (Atlas Venture Opportunity Fund I, LP, Atlas Venture Opportunity Fund II, LP, and Atlas Venture Fund XII, L.P.) where Kevin Bitterman, a director of Disc Medicine, Inc., is a member of the general partners' LLCs. He disclaims beneficial ownership except for his pecuniary interest.

Stakeholder Impact

• Shareholders: May perceive the insider selling as a negative signal, potentially leading to downward pressure on the stock price.

Next Steps

• The filing does not mention any specific future actions, events, or milestones for the company.

Key Dates

Recommendation

While the significant insider selling by a director, albeit indirectly through associated funds, could be perceived negatively, the fact that these transactions were executed under a Rule 10b5-1 plan mitigates the immediate bearish signal. A 10b5-1 plan suggests the sales were pre-scheduled and not based on new, non-public information. Without additional company-specific news or financial updates, a 'hold' recommendation is appropriate, advising investors to monitor future company performance and additional insider activity rather than reacting solely to these pre-planned sales.

Keywords

Disc Medicine, IRON, Form 4, Insider Selling, Kevin Bitterman, Director, Stock Sale, Beneficial Ownership, Atlas Venture, Rule 10b5-1